南美超级胎牛血清999尝鲜特惠转染试剂低至5折基质胶阶梯特惠积分商城,好礼送不停南美超级胎牛血清999尝鲜特惠转染试剂低至5折基质胶阶梯特惠积分商城,好礼送不停

翌圣生物-成为生命科学工具产业领导者-分子/蛋白/细胞生物学科研试剂供应商

Molecular basis of the HPV E7-ZER1 axis reveals a ligandable vulnerability in HPV-positive cancers

Xiaolu Wang, Chenhao Jiang, Yueling Zhao, Ruiyan Li, Yangyang Zhou, Shiqi Yin, Jin Chen, Shuxin Yan, Shuhua Gu, Xinying Li, Ying Yu, Yuchao Gu, Cheng Dong, Wenyi Mi

Journal:Cell Reports

IF:7.7

DOI:10.1016/j.celrep.2026.117740

PMID:42519832

Published:2026-07-28

research field:分子生物学基因治疗疫苗学免疫学RNA生物技术

Abstract

Persistent infection with high-risk human papillomaviruses (HPVs), notably HPV-16 and HPV-18, underlies most cervical cancers and many head and neck cancers. Here, we report the structural and functional basis by which the viral oncoprotein E7 hijacks host CRL2 ZER1 to degrade retinoblastoma (Rb) protein and drive E2F-dependent proliferation. Crystal structures reveal that the N-terminal MH/N-degron of E7 engages a defined pocket within the armadillo (ARM)-repeat domain of ZER1. Disruption of this interface abolishes E7-ZER1 binding, prevents Rb degradation, silences E2F transcriptional programs, and impairs proliferation of HPV-positive cancer cells. Guided by these insights, we identify a first-in-class small-molecule inhibitor that blocks E7-ZER1 association, restores Rb stability, and selectively suppresses HPV-positive tumor growth in vivo . These results define a viral mimicry mechanism and nominate the ZER1 degron pocket as a ligandable therapeutic target for HPV-driven malignancies, highlighting translational opportunities for targeted therapy.

本文使用的Yeasen产品

购物车
客服
转染试用